Pasternak AL - Search Results

1

Integration of Germline Pharmacogenetics Into a Tumor Sequencing Program.

Hertz DL, Glatz A, Pasternak AL, Lonigro RJ, Vats P, Wu YM, Anderson B, Rabban E, Mora E, Frank K, Robinson DR, Mody RJ, Chinnaiyan A. Hertz DL, et al. Among authors: pasternak al. JCO Precis Oncol. 2018;2:PO.18.00011. doi: 10.1200/po.18.00011. Epub 2018 Jul 23. JCO Precis Oncol. 2018. PMID: 32832831 Free PMC article.

2

Institutional profile of pharmacogenetics within University of Michigan College of Pharmacy.

Hertz DL, Luzum JA, Pasternak AL, Ward KM, Zhu HJ, Rae JM, Ellingrod VL. Hertz DL, et al. Among authors: pasternak al. Pharmacogenomics. 2017 Jul 26. doi: 10.2217/pgs-2017-0107. Online ahead of print. Pharmacogenomics. 2017. PMID: 28745551

3

Germline genetic variants with implications for disease risk and therapeutic outcomes.

Pasternak AL, Ward KM, Luzum JA, Ellingrod VL, Hertz DL. Pasternak AL, et al. Physiol Genomics. 2017 Oct 1;49(10):567-581. doi: 10.1152/physiolgenomics.00035.2017. Epub 2017 Sep 8. Physiol Genomics. 2017. PMID: 28887371 Free PMC article. Review.

4

Development of the CNS TAP tool for the selection of precision medicine therapies in neuro-oncology.

Linzey JR, Marini BL, Pasternak A, Smith C, Miklja Z, Zhao L, Kumar-Sinha C, Paul A, Harris N, Robertson PL, Hoffman LM, Chinnaiyan A, Mody R, Koschmann C. Linzey JR, et al. J Neurooncol. 2018 Mar;137(1):155-169. doi: 10.1007/s11060-017-2708-1. Epub 2017 Dec 12. J Neurooncol. 2018. PMID: 29235051 Free PMC article.

5

CYP3A pharmacogenetic association with tacrolimus pharmacokinetics differs based on route of drug administration.

Pasternak AL, Zhang L, Hertz DL. Pasternak AL, et al. Pharmacogenomics. 2018 Apr;19(6):563-576. doi: 10.2217/pgs-2018-0003. Epub 2018 Apr 9. Pharmacogenomics. 2018. PMID: 29629825 Review.

6

Impact of CYP3A5 phenotype on tacrolimus concentrations after sublingual and oral administration in lung transplant.

Pasternak AL, Kidwell KM, Dempsey JM, Gersch CL, Pesch A, Sun Y, Rae JM, Hertz DL, Park JM. Pasternak AL, et al. Pharmacogenomics. 2019 Apr;20(6):421-432. doi: 10.2217/pgs-2019-0002. Epub 2019 Apr 15. Pharmacogenomics. 2019. PMID: 30983501

7

Challenges to assess substrate-dependent allelic effects in CYP450 enzymes and the potential clinical implications.

Marcath LA, Pasternak AL, Hertz DL. Marcath LA, et al. Among authors: pasternak al. Pharmacogenomics J. 2019 Dec;19(6):501-515. doi: 10.1038/s41397-019-0105-1. Epub 2019 Oct 15. Pharmacogenomics J. 2019. PMID: 31616046 Review.

8

Patients carrying DPYD variant alleles have increased risk of severe toxicity and related treatment modifications during fluoropyrimidine chemotherapy.

Shakeel F, Fang F, Kwon JW, Koo K, Pasternak AL, Henry NL, Sahai V, Kidwell KM, Hertz DL. Shakeel F, et al. Among authors: pasternak al. Pharmacogenomics. 2021 Feb;22(3):145-155. doi: 10.2217/pgs-2020-0154. Epub 2021 Jan 7. Pharmacogenomics. 2021. PMID: 33410339

9

Impact of Pharmacogenetics on Intravenous Tacrolimus Exposure and Conversions to Oral Therapy.

Pasternak AL, Marcath LA, Li Y, Nguyen V, Gersch CL, Rae JM, Frame D, Scappaticci G, Kidwell KM, Hertz DL. Pasternak AL, et al. Transplant Cell Ther. 2022 Jan;28(1):19.e1-19.e7. doi: 10.1016/j.jtct.2021.09.011. Epub 2021 Sep 25. Transplant Cell Ther. 2022. PMID: 34583027 Free article.

10

SLCO1B3 polymorphisms and clinical outcomes in kidney transplant recipients receiving mycophenolate.

Schumacher L, Fang F, Kidwell KM, Shakeel F, Hertz DL, Park JM, Pasternak AL. Schumacher L, et al. Among authors: pasternak al. Pharmacogenomics. 2021 Nov;22(17):1111-1120. doi: 10.2217/pgs-2021-0102. Epub 2021 Oct 6. Pharmacogenomics. 2021. PMID: 34612072

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

32 results

Search Page

Filters